SAVA, a London startup reinventing health monitoring with its real-time, affordable and painless microsensors, has raised $8 million in seed funding. The investment round was led by Balderton Capital (which invested in Qargo and trawa) and Exor Ventures (which invested in Zeliq and Forta).
This funding round brings the total raised by the company to $13 million.. The team has grown to over 40 people since its debut. The funding will be used to further expand SAVA’s team, design its next-generation product line with high-throughput manufacturing capability, and demonstrate the platform’s clinical performance.
James Wise, Partner, Balderton said: “This could be the defining product in personal health monitoring in the coming decade, and an essential tool for patients and clinicians in diagnosing and treating many chronic diseases as well. Renato and Rafael have a compelling user-centric vision to revolutionise chronic disease management and preventative care, and the credibility and knowledge to execute in this vital area.”
“SAVA’s unique approach and novel technology underline its potential to become a foundation of a new healthcare system. It offers a platform that addresses the needs of both patients and healthcare systems and which will allow other companies to build upon.” – said Noam Ohana and Ileana Pirozzi, of Exor Ventures.
What does SAVA do?
Founded by Renato Circi and Rafael Michali, bioengineers from Imperial College London, SAVA has developed a microsensing device to detect molecules in the interstitial fluid, just under the skin. Its smart, connected wearable patch has been designed to streamline this data and deliver it directly to a user’s phone. The microsensor offers pain-free, real-time insights for users at a more affordable price.
SAVA’s first microsensor is focused on glucose monitoring for people with diabetes, which is projected to impact 1 in 8 adults.
The startup recently gained approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to go ahead with clinical trials on patients with diabetes, which will help the company validate its technology on a larger scale.
With its modular design, SAVA’s sensor will be able to simultaneously monitor multiple molecules. Multi-analyte sensing unlocks the ability to monitor a vast range of conditions from chronic conditions, to next-gen wellbeing applications, drug adherence to personalised therapy and more. The company aims to power the next era of healthcare with this offering.
Renato Circi, co-founder, SAVA said: “At SAVA we are tackling preventable illness by building a new operating system for health monitoring. Our microsensor will revolutionise healthcare by making world-leading monitoring technology available to all. With this capital, we can accelerate our goal of creating a new paradigm for healthcare – preventative, personalised and painless.”
Rafael Michali, co-founder, SAVA said: “SAVA’s mission is to transform healthcare from a curative to a preventative system, by empowering people to take control of their health through effortless access to real-time health insights. The current healthcare system cannot meet this demand and SAVA will bridge this gap by providing the foundational architecture of a new biosensing ecosystem.”
What do we think about SAVA?
The London startup is revolutionising health monitoring with its innovative, pain-free microsensors. With the latest funding, it aims to expand its team, enhance product design, and validate its technology through clinical trials.
It’s solution promises to transform chronic disease management and preventative care, positioning itself as a key player in the future of personalised healthcare.
